Miniatura

Fitxers

lvad160.pdf (988.77 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-11-30

Llicència de publicació

cc by-nc (c) Salvia, Anna La et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/207657

Metabolomic profile of neuroendocrine tumors (NETs) identifies methionine, porphyrin and tryptophan metabolism as key dysregulated pathways associated with patient survival

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1093/ejendo/lvad160

Resum

Objective: Metabolic profiling is a valuable tool to characterize tumor biology but remains largely unexplored in neuroendocrine tumors (NETs). Our aim was to comprehensively assess the metabolomic profile of NETs and identify novel prognostic biomarkers and dysregulated molecular pathways.Design and Methods: Multiplatform untargeted metabolomic profiling (GC-MS, CE-MS, and LC-MS) was performed in plasma from 77 patients with G1-2 extra-pancreatic NETs enrolled in the AXINET trial (NCT01744249) (study cohort) and from 68 non-cancer individuals (control). The prognostic value of each differential metabolite (n = 155) in NET patients (P < .05) was analyzed by univariate and multivariate analyses adjusted for multiple testing and other confounding factors. Related pathways were explored by Metabolite Set Enrichment Analysis (MSEA) and Metabolite Pathway Analysis (MPA).Results: Thirty-four metabolites were significantly associated with progression-free survival (PFS) (n = 16) and/or overall survival (OS) (n = 27). Thirteen metabolites remained significant independent prognostic factors in multivariate analysis, 3 of them with a significant impact on both PFS and OS. Unsupervised clustering of these 3 metabolites stratified patients in 3 distinct prognostic groups (1-year PFS of 71.1%, 47.7%, and 15.4% (P = .012); 5-year OS of 69.7%, 32.5%, and 27.7% (P = .003), respectively). The MSEA and MPA of the 13-metablolite signature identified methionine, porphyrin, and tryptophan metabolisms as the 3 most relevant dysregulated pathways associated with the prognosis of NETs.Conclusions: We identified a metabolomic signature that improves prognostic stratification of NET patients beyond classical prognostic factors for clinical decisions. The enriched metabolic pathways identified reveal novel tumor vulnerabilities that may foster the development of new therapeutic strategies for these patients.

Descripció

Matèries

Triptòfan, Porfirines

Matèries (anglès)

Tryptophan, Porphyrins

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SALVIA, Anna la, LENS PARDO, Alberto, LÓPEZ LÓPEZ, Angel, CARRETERO PUCHE, Carlos, CAPDEVILA, Jaume, BENAVENT, Marta, JIMÉNEZ FONSECA, Paula, CASTELLANO, Daniel, ALONSO, Teresa, TEULE, Alexandre, CUSTODIO, Ana, TAFUTO, Salvatore, CASTA, Adelaida la, SPADA, Francesca, LOPEZ GONZALVEZ, Angeles, GIL CALDERON, Beatriz, ESPINOSA OLARTE, Paula, BARBAS, Coral, GARCIA CARBONERO, Rocio, SOLDEVILLA, Beatriz. Metabolomic profile of neuroendocrine tumors (NETs) identifies methionine, porphyrin and tryptophan metabolism as key dysregulated pathways associated with patient survival. _European Journal of Endocrinology_. 2023. Vol. 190, núm. 1, pàgs. 62-74. [consulta: 10 de desembre de 2025]. ISSN: 1479-683X. [Disponible a: https://hdl.handle.net/2445/207657]

Exportar metadades

JSON - METS

Compartir registre